Biotech

Global advocacy platform born out of need during COVID-19 expands offerings with the goal of helping better support patients as they navigate health care systems

Today, Bristol Myers Squibb (NYSE: BMY) and GRYT Health unveiled the "Advocacy Exchange," an evolution of the existing COVID Advocacy Exchange, an enduring community built to support patient advocacy organizations by providing access to educational resources, encouraging ongoing dialogue, and sharing best practices among participants.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005908/en/

(Graphic: Bristol Myers Squibb)

(Graphic: Bristol Myers Squibb)

The Advocacy Exchange is a virtual platform created to unite advocacy organizations, patients, and industry leaders, enabling the exchange of information among users. It is a global collaboration, co-created, co-led and "always on" to foster meaningful partnerships across disease areas to improve patients' lives and positively impact their livelihood.

"While the pandemic and its effects continue to be felt, we are moving into a new chapter with The Exchange," said Cathy Traz, Executive Director, Patient Advocacy, Bristol Myers Squibb. "The new platform is a natural extension of our desire to expand educational resources available to patient advocacy groups so we can better serve the advocacy community's needs, both now and in the foreseeable future."

"As we engage in conversations with the global patient advocacy community, we hope the Advocacy Exchange will allow us to create lasting relationships," said David Craig, GRYT Health Co-Founder and CEO. "By adding to the fuel that drives advocacy efforts – information around issue areas of great importance and the passion for change – we are hopeful we can make a difference in the lives of patients around the world."

The Advocacy Exchange will keep key elements of the COVID Advocacy Exchange, including live virtual sessions, Working Group discussions and the provision of on-demand resources, all available 24/7, along with new features such as a newsroom, searchable resource library and a chatroom for Working Groups. Planned future updates include an opt-in member directory, "Ask an Advocate" forum, a method for participants to submit ideas and the creation of dedicated social channels to support community engagement, which will go online soon.

The establishment of Working Groups earlier this year is an example of how the Advocacy Exchange has already responded to the community's desires. These groups focus on addressing issues related to racial, ethnic, and other health disparities, access to care, the patient voice and patient-focused drug development and the future of advocacy.

"Together, we have created a safe space to voice our opinions, share insights and learn from one another," said Sheila Thorne, Racial & Ethnic Health and Healthcare Disparities Working Group lead and President and CEO, Multicultural Healthcare Marketing Group LLC. "I am excited about the potential of our Working Groups and the broader Advocacy Exchange to create tangible outcomes that will facilitate positive societal changes."

About GRYT Health

GRYT Health is a digital oncology company that empowers people to be in charge of their own health through education, engagement and support. We offer a community free from judgment that focuses on humanity and the value each person brings.

Our mission is to improve quality of life and increase survival for people facing cancer through the relentless focus on patient experience. We put patients first and work with healthcare organizations that do the same. We use the patient voice to enhance drug development and access; and together, we are helping to move healthcare forward. Visit www.grythealth.com to learn more.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

corporatefinancial-news

Bristol Myers Squibb

Media Inquiries:
Media@BMS.com

Investors:
Tim Power
609-252-7509
timothy.power@bms.com

Nina Goworek
908-673-9711
nina.goworek@bms.com

News Provided by Business Wire via QuoteMedia

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx for Treatment of Acute Myocarditis

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announced today that the first patient has been enrolled in ARCHER, the Company's Phase II, multi-center, international, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. CardiolRx is a pharmaceutically produced oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Gilead Sciences Announces Second Quarter 2022 Financial Results

Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion

Oncology Sales Increased 71% Year-Over-Year to $527 million

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aptose Reports Results for the Second Quarter 2022

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─

─ HM43239 Complete Remissions and Safety Across Three Dose Levels and Multiple Genotypic Subpopulations ─

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday Aug. 8, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented on LUMAKRAS ® (sotorasib) in combination with immunotherapy and in combination with a SHP2 inhibitor in non-small cell lung cancer, as well as tarlatamab data in small cell lung cancer.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases

  • New strategic collaboration leverages Sosei Heptares' StaR ® technology and SBDD platform and AbbVie's extensive neuroscience expertise
  • Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseases
  • Sosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties

Sosei Group Corporation ("the Company"; TSE: 4565) and ABBVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

The new agreement will leverage Sosei Heptares' StaR ® technology and structure-based drug design (SBDD) platform and AbbVie's extensive neuroscience and disease area expertise. The agreement expands the breadth of the ongoing collaboration between Sosei Heptares and AbbVie, building on the first multi-target discovery agreement signed between the companies in June 2020, which is focused on the inflammatory and autoimmune disease areas.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×